New Oncologics Overwhelmingly Approved In US Before EU

Ninety-five percent of novel cancer treatments approved in both the US and Europe received the FDA’s OK first, but Europe usually followed within a year, a Pink Sheet analysis shows.

cancer ribbons
The US has been taking home the ribbons in the race for oncology approvals. • Source: Shutterstock

The US Food and Drug Administration beats the European Medicines Agency to approval of novel agents across the board, but the imbalance is even more stark in oncology, the largest therapy area, a Pink Sheet analysis found.

European approval preceded the FDA’s assent for only one of the 22 cancer therapeutics approved in the US or the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Regional Comparisons

More from Pink Sheet